Skip to main content

Education

  • Doctor (MD), University of Oslo (2001)
  • Specialist in rheumatology (2015)
  • Doctoral degree (PhD) at the Department of Clinical Medicine, University of Oslo (2009)

Score

  • Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
  • Senior physician in rheumatology, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital

Field of interest

  • Rheumatology
  • Arthritic diseases
  • Immunotherapy
  • Anti-rheumatic disease-modifying drugs

Other

  • Head of the National Clinical Network in REMEDY

Email

This email address is being protected from spambots. You need JavaScript enabled to view it.

Telephone

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

NORTH STAR

The Nordic study of strategy tests and registries for rheumatic diseases

Project Manager:
Espen A. Haavardsholm
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related side effects in patients treated with immunotherapy

Project Manager:
Marte Schrumpf Heiberg
WP2 - PPhenotyping for personalized medicine

START

Stratification of acute inflammatory arthritis

Project Manager:
Silje Watterdal Syversen

Publications

Publications taken from the National Science Archive (NVA):

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Violetta Dubovyk, Georgios K. Vasileiadis, Tahzeeb Fatima, Yuan Zhang, Meliha Crnkic Kapetanovic, Alf Kastbom


RMD Open

2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

Kristina Lend, Frieda A. Koopman, Jon Lampa, Gerrit Jansen, Merete L. Hetland, Till Uhlig


Arthritis & Rheumatology

2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial

Mikkel Østergaard, Ronald F Van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström


Annals of the Rheumatic Diseases

2023

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial

Kristina Lend, Ronald F van Vollenhoven, Jon Lampa, Merete Lund Hetland, Espen A. Haavardsholm, Dan Nordström


The Lancet Rheumatology

2022

Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis

Jonathan Aldridge, Anna-Carin Lundell, Kerstin Andersson, Linda Mark, Merete Lund Hetland, Mikkel Østergaard


Clinical and Experimental Rheumatology

2021

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.

Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf


Arthritis Research & Therapy

2021

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial

Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan C. Nordström, Michael Nurmohamed, Bjorn Gudbjornsson


The BMJ

2020

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)

Manuel Ramos-Casals, Alexandre Maria, María E. Suarez-Almazor, Olivier Lambotte, Benjamin A. Fisher, Gabriela Hernández-Molina


Clinical and Experimental Rheumatology

2019

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study

Daniel Glinatsi, Marte Schrumpf, Anna Rudin, Dan C. Nordström, Espen A. Haavardsholm, Björn Gudbjörnsson


Trials

2017

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study

Karen Minde Fagerli, Desirée van der Heijde, Marte Schrumpf Heiberg, Ada Wierød, Synnøve Kalstad, Erik Rødevand


Rheumatology

2014

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte S. Heiberg, Åse Lexberg, Erik Rødevand


Annals of the Rheumatic Diseases

2014

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte Schrumpf, Synnøve Kalstad, Erik Rødevand


Annals of the Rheumatic Diseases

2013

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

Karen Minde Fagerli, Elisabeth Lie, Desirée van der Heijde, Marte Schrumpf, Cecilie Kaufmann, Erik Rødevand


Rheumatology

2012

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis

Elisabeth Lie, Désirée Van der Heijde, Till Uhlig, Wenche Koldingsnes, Erik Rødevand, Cecilie Kaufmann


Annals of the Rheumatic Diseases

2010